CHI3L1, chitinase 3 like 1, 1116

N. diseases: 420; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0043144
Disease: Wheezing
Wheezing 		0.010 AlteredExpression phenotype BEFREE YKL-40 levels in healthy controls (13.6 (11.0-17.0)) tended to be lower than those during acute wheeze (p = 0.07) and 3-month follow-up (p = 0.04), but were no different at the 1-year follow-up. 27732738 2017
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.010 Biomarker disease BEFREE In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas. 17146289 2006
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism 		0.010 GeneticVariation phenotype BEFREE Compared with rs4950928 GG homozygosity, presence of C-allele was associated with a doubling (CG) or tripling (CC) in YKL-40 levels, but not with risk of venous thromboembolism. 26988593 2016
CUI: C1402315
Disease: Vascular lesions
Vascular lesions 		0.020 AlteredExpression disease BEFREE YKL-40 is a novel marker of inflammation, tissue remodeling, and highly expressed in macrophages inside vascular lesions. 28941940 2018
CUI: C1402315
Disease: Vascular lesions
Vascular lesions 		0.020 Biomarker disease BEFREE In animals, increased of YKL-40 was associated with abnormal vascular lesions that were similar to CCMs. 30948312 2019
CUI: C0947751
Disease: Vascular inflammations
Vascular inflammations 		0.010 GeneticVariation phenotype BEFREE In T2DM patients without established cardiovascular disease, novel indices of vascular inflammation (NGAL and YKL-40) were associated with subclinical atherosclerosis (arterial stiffness) but also with adverse clinical prognosis. 29288632 2018
CUI: C3267003
Disease: Vascular endothelial growth factor overexpression
Vascular endothelial growth factor overexpression 		0.010 AlteredExpression disease BEFREE Band densitometric analyses showed that increasing YKL-40 expression was followed by VEGF overexpression, especially in MG-63s. 28030810 2017
CUI: C2145472
Disease: Urothelial Carcinoma
Urothelial Carcinoma 		0.010 AlteredExpression disease BEFREE We performed immunohistochemical study to evaluate CHI3L1 expression in 2 well-defined cohorts of urothelial carcinoma, including UTUC (n = 340) and UBUC (n = 295). 30660494 2019
CUI: C0042029
Disease: Urinary tract infection
Urinary tract infection 		0.010 AlteredExpression group BEFREE Determining the levels of urinary YKL-40/Cr may help identify true cases of UTI in febrile young children, especially when they have pyuria but not nitrite, or have neither pyuria nor nitrite in the urine. 29071817 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.020 Biomarker disease BEFREE The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with Crohn's disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy controls [HCs]. 30753386 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis 		0.020 AlteredExpression disease BEFREE The expression of CHI3L1 protein clearly was detectable in lamina propria and colonic epithelial cells (CECs) in several murine colitis models and ulcerative colitis and Crohn's disease patients but absent in normal controls. 16472595 2006
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 Biomarker phenotype BEFREE Enzymatically inactive chitinase-like protein CHI3L1 drives inflammatory response and promotes tumor progression. 30165890 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 Biomarker phenotype BEFREE CHI3L1 seems to contribute to the proliferation, migration, and neoplastic progression of colonic epithelial cells (CECs) under inflammatory conditions. 23170831 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 Biomarker phenotype BEFREE Taken together, our findings implicate fibroblast-derived Chi3L1 as a novel key player in the complex reciprocal interactions of stromal cells that facilitate tumor progression and metastasis, and suggest that targeting Chi3L1 may be clinically beneficial in breast cancer. 28368410 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 Biomarker phenotype BEFREE These results suggest a potential role of CHI3L1 in angiogenesis in IDC and may suggest its involvement in cancer progression. 29848684 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 Biomarker phenotype BEFREE CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma. 30301907 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 AlteredExpression phenotype BEFREE Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival. 31685562 2020
CUI: C0598935
Disease: Tumor Initiation
Tumor Initiation 		0.010 Biomarker phenotype BEFREE In experimental models YKL-40 supports tumor initiation through binding to RAGE, and is able to induce cancer cell proliferation via ERK1/2-MAPK pathway. 26733160 2016
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.020 Biomarker phenotype BEFREE Collectively, this study demonstrates Chi3l1 is a regulator of Th1 and CTL which could be a therapeutic target to enhance anti-tumor immunity. 29403003 2018
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.020 Biomarker phenotype BEFREE This study first suggests that Chi3l1 is a novel regulator of Th1/CTL responses and could be a target for treating cancer to increase tumor immunity.[BMB Reports 2018; 51(5): 207-208]. 29699605 2018
CUI: C1519678
Disease: Tumor Expansion
Tumor Expansion 		0.010 AlteredExpression phenotype BEFREE Clinical studies have shown that serum YKL-40 levels have a positive correlation with tumor expansion, in addition to being a prognostic agent independent of a short relapse-free interval, as well as a brief overall survival in patients with various cancers. 30426549 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE CHI3L1 expression was significantly associated with tumor size (P= 0.0001), lymph node metastasis (P< 0.0001), distant organ metastasis (P< 0.0001), extrathyroid invasion (P= 0.0022), vascular invasion (P= 0.0004) and TNM stage (P= 0.0001). 28009325 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 Biomarker phenotype BEFREE Effects of a Small Interfering RNA Targeting YKL-40 Gene on the Proliferation and Invasion of Endometrial Cancer HEC-1A Cells. 27465891 2016
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE CHI3L1 upregulation occurred during GC development, and positively correlated with GC invasion depth, lymph node status, and tumor staging. 30165890 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE The expression level of YKL-40 was positively correlated with cell migration and invasion. 28861166 2017